Keith Al-Hasani, Safiya Naina Marikar, Harikrishnan Kaipananickal, Scott Maxwell, Jun Okabe, Ishant Khurana, Thomas Karagiannis, Julia J Liang, Lina Mariana, Thomas Loudovaris, Thomas Kay, Assam El-Osta. EZH2 inhibitors promote β-like cell regeneration in young and adult type 1 diabetes donors.Signal transduction and targeted therapy. 2024, 9 (1): 2
Yichu Fu, Bi Zhang, Jianfeng Liu. Tripartite motif-containing protein 11 (TRIM11): a novel weapon against Alzheimer's disease.Signal transduction and targeted therapy. 2024, 9 (1): 3
Minyang Fu, Yuan Hu, Tianxia Lan, Kun-Liang Guan, Ting Luo, Min Luo. Correction: The Hippo signalling pathway and its implications in human health and diseases.Signal transduction and targeted therapy. 2024, 9 (1): 5
Bonan Chen, Peiyao Yu, Wai Nok Chan, Fuda Xie, Yigan Zhang, Li Liang, Kam Tong Leung, Kwok Wai Lo, Jun Yu, Gary M K Tse, Wei Kang, Ka Fai To. Cellular zinc metabolism and zinc signaling: from biological functions to diseases and therapeutic targets.Signal transduction and targeted therapy. 2024, 9 (1): 6
Yiqun Han, Jiayu Wang, Tao Sun, Quchang Ouyang, Jianwen Li, Jie Yuan, Binghe Xu. Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer.Signal transduction and targeted therapy. 2023, 8 (1): 429
Chi Wang Ip, Jörg Wischhusen. Versatile guardians: regenerative regulatory T cells in Parkinson's disease rodent models.Signal transduction and targeted therapy. 2023, 8 (1): 430